hematopoietic stem cell transplantation

Summary

Summary: Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.

Top Publications

  1. ncbi SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells
    Mark J Kiel
    Howard Hughes Medical Institute and Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
    Cell 121:1109-21. 2005
  2. pmc Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo
    Nathalia Holt
    Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
    Nat Biotechnol 28:839-47. 2010
  3. ncbi LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1
    S Hacein-Bey-Abina
    INSERM Unit 429, Cedex 15, France
    Science 302:415-9. 2003
  4. pmc Reduced mortality after allogeneic hematopoietic-cell transplantation
    Ted A Gooley
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    N Engl J Med 363:2091-101. 2010
  5. ncbi Development of a human adaptive immune system in cord blood cell-transplanted mice
    Elisabetta Traggiai
    Institute for Research in Biomedicine IRB, Via Vela 6, 6500 Bellinzona, Switzerland
    Science 304:104-7. 2004
  6. ncbi Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease
    Olle Ringden
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 81:1390-7. 2006
  7. pmc Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice
    Fumihiko Ishikawa
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, 44 Binney St, no 770, Boston, MA 02115, USA
    Blood 106:1565-73. 2005
  8. ncbi Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
    Loredana Ruggeri
    Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, Perugia University School of Medicine, Perugia, Italy
    Science 295:2097-100. 2002
  9. ncbi Osteoblastic cells regulate the haematopoietic stem cell niche
    L M Calvi
    Endocrine Unit, Department of Medicine, Center for Human Genetics and Molecular Pediatric Disease, University of Rochester School of Medicine, Rochester, New York 14642, USA
    Nature 425:841-6. 2003
  10. ncbi Competing risk analysis using R: an easy guide for clinicians
    L Scrucca
    Statistics Section, Department of Economy Finance and Statistics, University of Perugia, Perugia, Italy
    Bone Marrow Transplant 40:381-7. 2007

Detail Information

Publications290 found, 100 shown here

  1. ncbi SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells
    Mark J Kiel
    Howard Hughes Medical Institute and Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
    Cell 121:1109-21. 2005
    ..Many HSCs were associated with sinusoidal endothelium in spleen and bone marrow, though some HSCs were associated with endosteum. HSCs thus occupy multiple niches, including sinusoidal endothelium in diverse tissues...
  2. pmc Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo
    Nathalia Holt
    Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
    Nat Biotechnol 28:839-47. 2010
    ..The demonstration that a minority of CCR5(-/-) HSPCs can populate an infected animal with HIV-1-resistant, CCR5(-/-) progeny supports the use of ZFN-modified autologous hematopoietic stem cells as a clinical approach to treating HIV-1...
  3. ncbi LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1
    S Hacein-Bey-Abina
    INSERM Unit 429, Cedex 15, France
    Science 302:415-9. 2003
    ..Thus, retrovirus vector insertion can trigger deregulated premalignant cell proliferation with unexpected frequency, most likely driven by retrovirus enhancer activity on the LMO2 gene promoter...
  4. pmc Reduced mortality after allogeneic hematopoietic-cell transplantation
    Ted A Gooley
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    N Engl J Med 363:2091-101. 2010
    ..Over the past decade, advances have been made in the care of patients undergoing transplantation. We conducted a study to determine whether these advances have improved the outcomes of transplantation...
  5. ncbi Development of a human adaptive immune system in cord blood cell-transplanted mice
    Elisabetta Traggiai
    Institute for Research in Biomedicine IRB, Via Vela 6, 6500 Bellinzona, Switzerland
    Science 304:104-7. 2004
    ..This provides a valuable model to study development and function of the human adaptive immune system in vivo...
  6. ncbi Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease
    Olle Ringden
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 81:1390-7. 2006
    ..Mesenchymal stem cells (MSC) have immunomodulatory effects. The aim was to study the effect of MSC infusion on graft-versus-host disease (GVHD)...
  7. pmc Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice
    Fumihiko Ishikawa
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, 44 Binney St, no 770, Boston, MA 02115, USA
    Blood 106:1565-73. 2005
    ..Thus, the NOD/SCID/IL2rgamma(null) newborn system might be an important experimental model to study the human hemato-lymphoid system...
  8. ncbi Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
    Loredana Ruggeri
    Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, Perugia University School of Medicine, Perugia, Italy
    Science 295:2097-100. 2002
    ..NK cell alloreactivity may thus provide a powerful tool for enhancing the efficacy and safety of allogeneic hematopoietic transplantation...
  9. ncbi Osteoblastic cells regulate the haematopoietic stem cell niche
    L M Calvi
    Endocrine Unit, Department of Medicine, Center for Human Genetics and Molecular Pediatric Disease, University of Rochester School of Medicine, Rochester, New York 14642, USA
    Nature 425:841-6. 2003
    ..Niche constituent cells or signalling pathways provide pharmacological targets with therapeutic potential for stem-cell-based therapies...
  10. ncbi Competing risk analysis using R: an easy guide for clinicians
    L Scrucca
    Statistics Section, Department of Economy Finance and Statistics, University of Perugia, Perugia, Italy
    Bone Marrow Transplant 40:381-7. 2007
    ..We provide all the instructions for downloading it from internet and illustrate how to use it for analysis of a sample dataset of patients who underwent haematopoietic stem cell transplantation for acute leukaemia...
  11. ncbi Hematopoietic stem-cell transplantation
    Edward A Copelan
    Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, USA
    N Engl J Med 354:1813-26. 2006
  12. pmc Stem-cell gene therapy for the Wiskott-Aldrich syndrome
    Kaan Boztug
    Department of Pediatric Hematology Oncology, Hannover Medical School, Hannover, Germany
    N Engl J Med 363:1918-27. 2010
    ..Funded by Deutsche Forschungsgemeinschaft and others; German Clinical Trials Register number, DRKS00000330.)...
  13. pmc Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells
    Anthony E Boitano
    Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 329:1345-8. 2010
    ..Mechanistic studies show that SR1 acts by antagonizing the aryl hydrocarbon receptor (AHR). The identification of SR1 and AHR modulation as a means to induce ex vivo HSC expansion should facilitate the clinical use of HSC therapy...
  14. ncbi Immunomodulation by mesenchymal stem cells and clinical experience
    K Le Blanc
    Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Intern Med 262:509-25. 2007
    ..Possible clinical applications include therapy-resistant severe acute graft-versus-host disease, tissue repair, treatment of rejection of organ allografts and autoimmune disorders...
  15. ncbi Graft-versus-host disease
    Warren D Shlomchik
    Yale University School of Medicine, sections of Medical Oncology and Immunobiology, PO Box 208032, New Haven, Connecticut 06520, USA
    Nat Rev Immunol 7:340-52. 2007
    ..This Review focuses on research in mouse models pursued to achieve this goal...
  16. ncbi Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients
    Hillard M Lazarus
    Department of Medicine, The University Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA
    Biol Blood Marrow Transplant 11:389-98. 2005
    ..The optimal MSC dose and frequency of administration to prevent or treat GVHD during allogeneic HSC transplantation should be evaluated further in phase II clinical trials...
  17. doi Molecular epidemiology of KI and WU polyomaviruses in infants with acute respiratory disease and in adult hematopoietic stem cell transplant recipients
    Maurizia Debiaggi
    Department of Morphological and Clinical Sciences, Section of Microbiology, University of Pavia, Pavia, Italy
    J Med Virol 82:153-6. 2010
    ..The results suggest that WU/KIPyVs have a limited circulation in Italy and a low pathogenic potential in young children. Brief and asymptomatic infection can occur in hematopoietic transplant recipients...
  18. ncbi Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients
    Kieren A Marr
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, WA, USA
    Clin Infect Dis 34:909-17. 2002
    ..of and risks for mould infections, we examined the records of 5589 patients who underwent hematopoietic stem cell transplantation at the Fred Hutchinson Cancer Research Center (Seattle) from 1985 through 1999...
  19. ncbi Purification and characterization of mouse hematopoietic stem cells
    G J Spangrude
    Department of Pathology, Stanford University School of Medicine, CA 94305
    Science 241:58-62. 1988
    ..Thirty of these cells are sufficient to save 50 percent of lethally irradiated mice, and to reconstitute all blood cell types in the survivors...
  20. pmc Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice
    Paul W Denton
    Department of Internal Medicine, Division of Infectious Diseases, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States of America
    PLoS Med 5:e16. 2008
    ..Given the importance of this route of transmission, we investigated the susceptibility of humanized mice to intravaginal HIV-1 infection...
  21. pmc Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation
    Ken Ichi Matsuoka
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 120:1479-93. 2010
    ..These studies indicate that CD4+ lymphopenia is a critical factor in Treg homeostasis and that prolonged imbalance of Treg homeostasis after HSCT can result in loss of tolerance and significant clinical disease manifestations...
  22. ncbi Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation
    Lynne M Ball
    Department of Pediatric Stem Cell Transplantation, Leiden University Medical Centre, Leiden, The Netherlands
    Blood 110:2764-7. 2007
    ..These data suggest that MSCs, possibly thanks to their potent immunosuppressive effect on alloreactive host T lymphocytes escaping the preparative regimen, reduce the risk of graft failure in haploidentical HSC transplant recipients...
  23. ncbi European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update
    J Maertens
    Department of Hematology, Leukemia and Stem Cell Transplantation Unit, University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium
    Bone Marrow Transplant 46:709-18. 2011
    ....
  24. ncbi Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors
    Kieren A Marr
    Fred Hutchinson Cancer Research Center Programs in Infectious Diseases and Long term Follow up, Seattle, WA 98109, USA
    Blood 100:4358-66. 2002
    ....
  25. ncbi New perspectives on the biology of acute GVHD
    S Paczesny
    Department of Pediatrics, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    Bone Marrow Transplant 45:1-11. 2010
    ..Herein, we provide a novel perspective on the immunobiology of acute GVHD and briefly discuss some of the outstanding questions and limitations of the model systems...
  26. ncbi Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice
    Willy A Noort
    Department of Hematology, Leiden University Medical Center, Leiden University Medical Center, The Netherlands
    Exp Hematol 30:870-8. 2002
    ..In cotransplantation experiments, we examined the homing of MSC as well as the effect on engraftment of human umbilical cord blood (UCB)-derived CD34(+) cells in NOD/SCID mice...
  27. ncbi Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir
    N Symeonidis
    Department of Medicine, Memorial Sloan Ketterring Cancer Center, New York, New York 10021, USA
    Transpl Infect Dis 9:108-13. 2007
    ..Cidofovir is currently being increasingly used for treatment of adenoviral infections after HSCT. The efficacy of cidofovir in patients with invasive adenoviral infection is not established...
  28. ncbi Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells
    In Kyung Park
    Division of Hematology Oncology, Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
    Nature 423:302-5. 2003
    ..Expression of p16Ink4a and p19Arf in normal HSCs resulted in proliferative arrest and p53-dependent cell death, respectively. Our results indicate that Bmi-1 is essential for the generation of self-renewing adult HSCs...
  29. ncbi Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival
    John E Wagner
    Blood and Marrow Transplant Program of the Department of Pediatrics, University of Minnesota Cancer Center and School of Medicine, Minneapolis 55455, USA
    Blood 100:1611-8. 2002
    ..7 x 10(5) CD34(+) cells per kilogram of recipient's body weight. Therefore, graft selection should be based principally on CD34 cell dose when multiple UCB units exist with an HLA disparity of 2 or less...
  30. ncbi Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study
    Jan W Gratama
    Department of Clinical and Tumor Immunology, Erasmus Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Blood 116:1655-62. 2010
    ..004). CMV tetramer-based immune monitoring, in conjunction with virologic monitoring, can be an important new tool to assess risk of CMV-related complications and to guide preemptive therapeutic choices...
  31. pmc WU and KI polyomavirus infections in pediatric hematology/oncology patients with acute respiratory tract illness
    Suchitra Rao
    Department of Pediatrics, B158 The Children s Hospital and University of Colorado School of Medicine, Aurora, CO 80045, USA
    J Clin Virol 52:28-32. 2011
    ..Other polyomaviruses (BKPyV and JCPyV) have been associated with illness in immunocompromised patients, and some studies suggest a higher prevalence of WUPyV and KIPyV in this population...
  32. pmc Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo
    Heather E Fleming
    Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Cell Stem Cell 2:274-83. 2008
    ..Wnt pathway activation in the niche is required to limit HSC proliferation and preserve the reconstituting function of endogenous hematopoietic stem cells...
  33. pmc Hematopoietic stem cell transplantation: a global perspective
    Alois Gratwohl
    European Group for Blood andMarrow Transplantation, Transplant Activity Survey Office, Department of Hematology, University Hospital Basel, Basel, Switzerland
    JAMA 303:1617-24. 2010
    b>Hematopoietic stem cell transplantation (HSCT) requires significant infrastructure. Little is known about HSCT use and the factors associated with it on a global level.
  34. ncbi Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation
    Katarina Le Blanc
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Biol Blood Marrow Transplant 11:321-34. 2005
    ..They are also of potential use in the treatment of organ transplant rejection and in autoimmune inflammatory bowel disorders where immunomodulation and tissue repair are needed...
  35. pmc Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation
    Michael A Brehm
    Diabetes Division, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Clin Immunol 135:84-98. 2010
    ..Our data define key parameters for establishing humanized mouse models to study human immunity...
  36. doi Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential
    David G Kent
    Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada
    Blood 113:6342-50. 2009
    ..These findings establish the identity of a phenotypically and molecularly distinct class of pluripotent hematopoietic cells with lifelong self-renewal capacity...
  37. ncbi Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts
    Charles E Murry
    Department of Pathology, Box 357470, Room D 514 HSB, University of Washington, Seattle, Washington 98195, USA
    Nature 428:664-8. 2004
    ..These results indicate that haematopoietic stem cells do not readily acquire a cardiac phenotype, and raise a cautionary note for clinical studies of infarct repair...
  38. ncbi Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome
    Alain Chapel
    Institut de Radioprotection et de Surete Nucleaire, IRSN DPHD SARAM, Fontenay aux Roses, France
    J Gene Med 5:1028-38. 2003
    ..We investigated the potential of a combined infusion of autologous ex vivo expanded hematopoietic cells with mesenchymal (MSCs) for the treatment of multi-organ failure syndrome following irradiation in a non-human primate model...
  39. doi Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial
    M L MacMillan
    Division of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Department of Pediatrics University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:447-54. 2009
    ..This encouraging safety profile with haploidentical MSCs supports the investigation of unrelated 'off the shelf' allogeneic HLA-mismatched MSC products...
  40. doi Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
    Rafael F Duarte
    Department of Hematology, ICO Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain
    J Clin Oncol 28:4492-9. 2010
    ....
  41. pmc Strategies to enhance umbilical cord blood stem cell engraftment in adult patients
    Colleen Delaney
    Fred Hutchinson Cancer Research Center, Mailstop D2 100, 1100 Fairview Ave N, PO Box, 9024, Seattle, WA 98109, USA
    Expert Rev Hematol 3:273-83. 2010
    ..This article will focus on ex vivo expansion of UCB HSCs and strategies to enhance UCB homing as potential solutions to overcome the problem of low stem cell numbers in a UCB graft...
  42. doi Long-term results of stem cell transplantation for MS: a single-center experience
    A Fassas
    Department of Hematology, Bone Marrow Transplantation and Gene and Cell Therapy Unit, Aristotle University of Thessaloniki Medical School, George Papanicolaou Hospital, Thessaloniki, Greece
    Neurology 76:1066-70. 2011
    ..To report long-term results of a phase I/II study conducted in a single center in order to investigate the effect of hemopoietic stem cell transplantation (HSCT) in the treatment of multiple sclerosis (MS)...
  43. doi Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation
    Lorenzo Moretta
    Giannina Gaslini Institute, Genova Quarto, Italy
    Blood 117:764-71. 2011
    ..In an allogeneic setting, such as T cell-depleted haploidentical hematopoietic stem cell transplantation, NK cells may express inhibitory killer immunoglobulin-like receptors that are not engaged by any ..
  44. pmc Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice
    Leonard D Shultz
    The Jackson Laboratory, Bar Harbor, ME 04609
    Proc Natl Acad Sci U S A 107:13022-7. 2010
    ....
  45. ncbi Functional and phenotypic characterization of the humanized BLT mouse model
    A K Wege
    Department of Internal Medicine, Division of Infectious Diseases Y9 206, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Curr Top Microbiol Immunol 324:149-65. 2008
    ..Importantly, in these mice the T cells developed in the human thymic implant are capable of being activated by human antigen-presenting cells and mount potent human MHC-restricted T cell immune responses...
  46. doi Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma
    John F DiPersio
    Division of Oncology, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Blood 113:5720-6. 2009
    ..This study is registered at www.clinicaltrials.gov as #NCT00103662...
  47. pmc Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates
    Emmanuelle Passegue
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Exp Med 202:1599-611. 2005
    ....
  48. pmc Highly active antiretroviral therapy potently suppresses HIV infection in humanized Rag2-/-gammac-/- mice
    Kaori Sango
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    AIDS Res Hum Retroviruses 26:735-46. 2010
    ..This animal model can serve as a valuable in vivo model to study the efficacy of anti-HIV therapies...
  49. pmc Mesenchymal stem cells in hematopoietic stem cell transplantation
    Minoo Battiwalla
    Department of Medicine, Roswell Park Cancer Institute, New York, New York, USA
    Cytotherapy 11:503-15. 2009
    ....
  50. ncbi Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality
    Arlo Upton
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109, USA
    Clin Infect Dis 44:531-40. 2007
    ..The aim of this study was to determine the probability of survival and prognostic factors associated with outcomes over a long period of time...
  51. pmc Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells
    J L Christensen
    Departments of Pathology and Developmental Biology, Stanford University School of Medicine, Stanford, CA 94305 5324, USA
    Proc Natl Acad Sci U S A 98:14541-6. 2001
    ..Fetal liver HSCs are contained within Flk-2(-) and Flk-2(+) KTLS cells...
  52. ncbi Protective conditioning for acute graft-versus-host disease
    Robert Lowsky
    Department of Medicine, Stanford University School of Medicine, Stanford, Calif, USA
    N Engl J Med 353:1321-31. 2005
    ..Conditioning with total lymphoid irradiation plus antithymocyte serum protects mice against acute graft-versus-host disease (GVHD) after hematopoietic-cell transplantation. We tested this strategy in humans...
  53. ncbi Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis
    Per Ljungman
    Department of Hematology, Huddinge University Hospital, SE 14186 Stockholm, Sweden
    Blood 102:4255-60. 2003
    ..Our data suggest that donor CMV status influences outcome of unrelated SCT. For a CMV-seropositive patient, a seropositive donor might be preferable...
  54. ncbi Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma
    Koen Van Besien
    Lymphoma Working Committee, International Bone Marrow Transplant Registry Autologous Blood and Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee, USA
    Blood 102:3521-9. 2003
    ..We did not detect a correlation between graft-versus-host disease (GVHD) and recurrence. Finally, outcomes of transplantation for follicular lymphoma show improvement over the past decade...
  55. ncbi Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database
    R Saccardi
    BMT Unit Department of Hematology, Ospedale di Careggi, Florence, Italy
    Mult Scler 12:814-23. 2006
    ....
  56. doi Transplant outcomes in mucopolysaccharidoses
    Vinod K Prasad
    Division of Pediatric Blood and Marrow Transplantation, Duke University Medical Center, Durham, NC 27710, USA
    Semin Hematol 47:59-69. 2010
    ..In contrast, allogeneic hematopoietic stem cell transplantation (HSCT) allows donor-derived, enzyme-producing cells to migrate to the brain and other organs to ..
  57. ncbi Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis
    Eyal Robenshtok
    Department of Medicine E, Rabin Medical Center, Petah Tiqva, Israel
    J Clin Oncol 25:5471-89. 2007
    ..Many studies have evaluated the role of antifungal prophylaxis in cancer patients, with inconsistent conclusions...
  58. pmc IL-15 trans-presentation promotes human NK cell development and differentiation in vivo
    Nicholas D Huntington
    Immunology Department, 2 Institut National de la Santé et de la Recherche Médicale U668, 3 INSERM U883, Unite de Regulation Immunitaire et Vaccinologie, Institut Pasteur, Paris 75724, France
    J Exp Med 206:25-34. 2009
    ....
  59. ncbi Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single center
    Olle Ringden
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 81:718-25. 2006
    Allogeneic hematopoietic stem cell transplantation (ASCT) is a possible cure for many inherited disorders.
  60. ncbi Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia
    Mary J Laughlin
    Case Comprehensive Cancer Center and University Hospitals of Cleveland Ireland Cancer Center, Cleveland, USA
    N Engl J Med 351:2265-75. 2004
    ..Data regarding the outcome of cord-blood transplantation in adults are scant, despite the fact that these grafts are increasingly used in adults...
  61. ncbi Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies
    Michael Boeckh
    University of Washington, Seattle, WA 81009, USA
    Biol Blood Marrow Transplant 9:543-58. 2003
    Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality after hematopoietic stem cell transplantation. Significant progress has been made in the prevention of CMV disease over the past decade, but prevention of late ..
  62. pmc Mesenchymal stem cell as salvage treatment for refractory chronic GVHD
    J Y Weng
    Department of Haematology, Guangdong General Hospital, Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, Guangdong, PR China
    Bone Marrow Transplant 45:1732-40. 2010
    ..In conclusion, transfusion of MSCs expanded in vitro, irrespective of the donor, might be a safe and effective salvage therapy for patients with steroid-resistant, cGVHD...
  63. pmc Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases
    Dominique Farge
    Service de Médecine Interne et Unité INSERM U 976, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, Paris 7 Université Denis Diderot, 1 avenue Claude Vellefaux, 75 010 Paris France
    Haematologica 95:284-92. 2010
    Autologous hematopoietic stem cell transplantation has been used since 1996 for the treatment of severe autoimmune diseases refractory to approved therapies...
  64. ncbi Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell
    D S Krause
    Department of Laboratory Medicine and, Yale University School of Medicine, New Haven, CT 06520, USA
    Cell 105:369-77. 2001
    ..This finding may contribute to clinical treatment of genetic disease or tissue repair...
  65. pmc Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates
    Brian C Beard
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Clin Invest 120:2345-54. 2010
    ..These nonhuman primate studies closely model a clinical setting and should have broad applications for HSC gene therapy targeting human diseases of malignant, genetic, and infectious nature, including HIV...
  66. ncbi Haematopoietic cell transplantation as immunotherapy
    F R Appelbaum
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D5-310, PO Box 19024, Seattle, Washington 98109-1024, USA
    Nature 411:385-9. 2001
    ..Recent advances in our understanding of the immunobiology of stem-cell engraftment, tolerance and tumour eradication are allowing clinicians to better harness this powerful effect...
  67. doi The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency
    Federico Serana
    Department of Biomedical Science and Biotechnology, University of Brescia, Italy
    J Immunol 185:7713-22. 2010
    ..If the disease is left untreated, it is likely to have a fatal outcome in early infancy. Because hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy with pegylated bovine ADA (PEG-ADA) are both provided in ..
  68. ncbi Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia
    V Rocha
    Eurocord-Cord Blood Transplant Group (CBTG) and Biostatistics Department, Saint Louis Hospital AP-HP, University of Paris 7, France
    Blood 97:2962-71. 2001
    ..39; 95CI: 0.97-1.99; P <.07). In conclusion, the use of UCBT, as a source of hematopoietic stem cells, is a reasonable option for children with AL lacking an acceptably matched unrelated marrow donor...
  69. ncbi Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation
    Jo Anne H van Burik
    University of Minnesota, Minneapolis, MN, USA
    Clin Infect Dis 39:1407-16. 2004
    ..would be an effective agent for antifungal prophylaxis during neutropenia in patients undergoing hematopoietic stem cell transplantation (HSCT)...
  70. pmc Adult T-cell leukemia/lymphoma development in HTLV-1-infected humanized SCID mice
    Prabal Banerjee
    Department Microbiology and Immunology, SUNY Upstate Medical University, Syracuse, NY, USA
    Blood 115:2640-8. 2010
    ..This animal model of ATLL will provide an important tool for the identification of molecular and cellular events that control the initiation and progression of the lymphoma and potential therapeutic targets to block tumor development...
  71. doi Update on therapy of chronic lymphocytic leukemia
    John G Gribben
    Barts Cancer Institute, Barts and London School of Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom
    J Clin Oncol 29:544-50. 2011
    ..Numerous novel agents are being developed, and their role in the first-line treatment of frail patients or those who relapse after previous treatment is being explored in clinical trials...
  72. doi Estimating unbiased haplotype frequencies from stem cell donor samples typed at heterogeneous resolutions: a practical study based on over 1 million German donors
    H P Eberhard
    ZKRD Zentrales Knochenmarkspender Register für Deutschland, German National Bone Marrow Donor Registry, Ulm, Germany
    Tissue Antigens 76:352-61. 2010
    ..We discuss algorithmic aspects of this approach and, also because of the sample size, provide some new insights into the distribution of HLA-DRB1 alleles in the German population and the application of HFs in unrelated donor search...
  73. pmc Deficiency of CD73/ecto-5'-nucleotidase in mice enhances acute graft-versus-host disease
    Hiroki Tsukamoto
    Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA
    Blood 119:4554-64. 2012
    ....
  74. ncbi Wnt proteins are lipid-modified and can act as stem cell growth factors
    Karl Willert
    Howard Hughes Medical Institute and Department of Developmental Biology, Stanford University School of Medicine, Stanford, California 94305, USA
    Nature 423:448-52. 2003
    ..The purified Wnt3a protein induces self-renewal of haematopoietic stem cells, signifying its potential use in tissue engineering...
  75. doi The impact of early viral infections and graft-versus-host disease on immune reconstitution following paediatric stem cell transplantation
    H Olkinuora
    Children s Hospital, Division of Hematology Oncology and Stem Cell Transplantation, Helsinki University Central Hospital, Helsinki, Finland
    Scand J Immunol 73:586-93. 2011
    ..GVHD) render an impact on both the clinical and immunological recovery following allogeneic hematopoietic stem cell transplantation (HSCT)...
  76. pmc Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation
    S R Marino
    Department of Pathology, University of Chicago Medical Center, Chicago, IL 60637 1470, USA
    Bone Marrow Transplant 47:217-26. 2012
    ..Random forest analysis is a novel statistical methodology for analysis of HLA mismatching and outcome studies, capable of identifying important amino acid substitutions missed by other methods...
  77. doi Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donors
    Angela R Smith
    Division of Pediatric Hematology Oncology Blood and Marrow Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 15:1086-93. 2009
    ....
  78. pmc A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model
    Saki Shimizu
    Department of Medicine, Division of Hematology Oncology, UCLA AIDS Institute, David Geffen School of Medicine, University of California Los Angeles, 615 Charles E Young Drive South, Los Angeles, CA 90095, USA
    Blood 115:1534-44. 2010
    ..These results demonstrate that lentiviral vector delivery of shRNA into human HPSCs could stably down-regulate CCR5 in systemic lymphoid organs in vivo...
  79. pmc In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets
    Andreas Beilhack
    Department of Medicine, Stanford University, Stanford, CA 94305, USA
    Blood 106:1113-22. 2005
    ..These findings underline the potential of T-cell subsets with defined trafficking patterns for immune reconstitution without the risk of GVHD...
  80. doi Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009
    P Ljungman
    Department of Haematology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 45:219-34. 2010
    ..The introduction of alternative therapies, such as imatinib for CML, has challenged well-established indications. An updated report with revised tables and operating definitions is presented...
  81. pmc Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies
    Marcelo C Pasquini
    Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    Biol Blood Marrow Transplant 16:1076-83. 2010
    Clinical investigation of autologous hematopoietic stem cell transplantation (HSCT) as therapy for multiple sclerosis (MS) has been ongoing for over a decade...
  82. pmc Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation
    Desiree Caselli
    U O Cure Domiciliari Terapia Cellulare, Dipartimento di Oncoematologia, Azienda Ospedaliero Universitaria Meyer, Viale Pieraccini, 24 50139 Firenze, Italy
    Haematologica 95:1612-5. 2010
    ..Monitoring local bacterial isolates epidemiology is mandatory and will allow empiric antibiotic therapy to be tailored to reduce fatalities...
  83. doi Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders
    Jaap J Boelens
    Department of Pediatrics, Blood and Marrow Transplantation Program, UMC Utrecht, Wilhelmina Children s Hospital, KC 03 063 0, Lundlaan 6, 3584 EA Utrecht, The Netherlands
    Pediatr Clin North Am 57:123-45. 2010
    ..expectations, and the risks and benefits associated with available therapies such as allogeneic hematopoietic stem cell transplantation (HSCT). This review discusses indications for HSCT and outcomes of HSCT for selected IMD...
  84. doi Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer
    Robert R Jenq
    Department of Immunology and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Nat Rev Cancer 10:213-21. 2010
    ..We highlight accomplishments made by researchers who continue to strive to improve outcomes for patients and increase the availability of this potentially life-saving therapy for patients with otherwise incurable malignancies...
  85. doi Hematopoietic stem cell transplantation for multiple myeloma beyond 2010
    Joan Blade
    Department of Hematology and Bone Marrow Transplant Unit, Institut of Hematology and Oncology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Blood 115:3655-63. 2010
    ..The development of novel reduced-intensity preparative regimens and peri- and posttransplantation strategies aimed at minimizing graft-versus-host disease, and enhancing the graft-versus-myeloma effect are key issues...
  86. doi Pregnancy and live birth after autotransplantation of frozen-thawed ovarian tissue in a patient with metastatic disease undergoing chemotherapy and hematopoietic stem cell transplantation
    Jacques Donnez
    Universite Catholique de Louvain, Institut de Recherche Expérimentale et Clinique IREC, Unité de Recherche GYNE, Department of Gynecology, Cliniques Universitaires Saint Luc, Brussels, Belgium
    Fertil Steril 95:1787.e1-4. 2011
    ..To report a live birth after orthotopic transplantation of cryopreserved ovarian tissue...
  87. doi Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation
    Claire Roddie
    UCL Cancer Institute, Department of Haematology, Paul O Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK
    Expert Opin Biol Ther 11:473-87. 2011
    Allogeneic hematopoietic stem cell transplantation (SCT) is the treatment of choice for many malignant hematological disorders...
  88. pmc The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment
    Bradford K Berges
    Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USA
    Retrovirology 8:65. 2011
    ....
  89. doi Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells
    Takashi Yahata
    Tokai University School of Medicine, Isehara, Kanagawa, Japan
    Blood 118:2941-50. 2011
    ..The study reveals that ROS play a causative role for DNA damage and the regulation of ROS have a major influence on human HSC aging...
  90. pmc Loss of neuronal integrity during progressive HIV-1 infection of humanized mice
    Prasanta K Dash
    Department of Pharmacology and Experimental Neuroscience, Radiology, Surgery, and Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA
    J Neurosci 31:3148-57. 2011
    ..As such, the model permits studies of the relationships between ongoing viral replication and virus-associated neurodegeneration...
  91. ncbi Bone loss following hematopoietic stem cell transplantation: a long-term follow-up
    Claudia M S Schulte
    Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany
    Blood 103:3635-43. 2004
    Transplantation-associated bone loss is a well-known phenomenon, however, effects of hematopoietic stem cell transplantation are insufficiently characterized...
  92. pmc Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice
    Kei Sato
    Laboratory of Viral Pathogenesis, Institute for Virus Research, Kyoto University, 53 Shogoinkawara cho, Sakyo ku, Kyoto, Kyoto 606 8507, Japan
    J Virol 84:9546-56. 2010
    ..Taken together, these results provide the evidence indicating that endogenous APOBEC3s are associated with G-to-A mutation of HIV-1 provirus in vivo, which can result in the abrogation of HIV-1 infection...
  93. doi Differential anti-inflammatory and anti-fibrotic activity of transplanted mesenchymal vs. hematopoietic stem cells in carbon tetrachloride-induced liver injury in mice
    Sivasami Pulavendran
    Department of Biotechnology Central Leather Research Institute, Adyar Chennai 600020, India
    Int Immunopharmacol 10:513-9. 2010
    ..Our findings suggest that bone marrow MSC are capable of alleviating the immunoreactions leading to the fibrosis in the liver...
  94. ncbi Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation
    Yoko Ogawa
    Institute for Advanced Medical Research, and Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan
    Cornea 22:S19-27. 2003
    ..To review the condition of dry eye associated with chronic graft-versus-host disease (GVHD)...
  95. pmc Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation
    Muzlifah Haniffa
    Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne NE2 4HH, England, UK
    J Exp Med 206:371-85. 2009
    Animal models of hematopoietic stem cell transplantation have been used to analyze the turnover of bone marrow-derived cells and to demonstrate the critical role of recipient antigen-presenting cells (APC) in graft versus host disease (..
  96. pmc Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis
    Francisco M Marty
    Division of Infectious Diseases, Boston, MA 02115, USA
    Blood 110:490-500. 2007
    ..Whether sirolimus has a similar effect on CMV reactivation after allogeneic hematopoietic stem cell transplantation (HSCT) is not known...
  97. ncbi Autologous stem cell transplantation in progressive multiple sclerosis--an interim analysis of efficacy
    A Fassas
    Department of Hematology, The George Papanicolaou General Hospital, Thessaloniki, Greece
    J Clin Immunol 20:24-30. 2000
    ....
  98. pmc HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/- (RAG-hu) mouse model
    Bradford K Berges
    Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA
    Retrovirology 3:76. 2006
    ..Thus, this model shows considerable promise to study long-term in vivo HIV infection and pathogenesis...
  99. ncbi High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis
    Arnaud Jaccard
    Department of Hematology, Centre Hospitalier Universitaire, Université et Centre National de la Recherche Scientifique, UMR 6101, Limoges, France
    N Engl J Med 357:1083-93. 2007
    ....
  100. doi Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system
    Tobias Alexander
    German Rheumatism Research Center, and Department of Rheumatology and Clinical Immunology, Charite Universitatsmedizin, Chariteplatz 1, Berlin, Germany
    Blood 113:214-23. 2009
    Clinical trials have indicated that immunoablation followed by autologous hematopoietic stem cell transplantation (ASCT) has the potential to induce clinical remission in patients with refractory systemic lupus erythematosus (SLE), but ..
  101. ncbi The use of growth factors in hematopoietic stem cell transplantation
    I Pusic
    Division of Oncology, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Curr Pharm Des 14:1950-61. 2008
    ..We also review the data on novel agents for mobilization of stem cells...

Research Grants99

  1. Post-transplant vaccines to enhance graft-versus-leukemia responses
    CATHERINE JU YING WU; Fiscal Year: 2010
    ..provided by applicant): A curative graft-versus-leukemia (GvL) response following allogeneic hematopoietic stem cell transplantation (HSCT) results from the: (1) restoration of normal immunity, thus overcoming leukemia- or ..
  2. Allogeneic Stem Cell Transplants for HPV+Cervical Cancer
    Alexander Fefer; Fiscal Year: 2003
    ..allogeneic adoptive T-cell immunotherapy in the context of non-myeloablative allogeneic hematopoietic stem cell transplantation (NST) for the treatment of non-hematologic malignancies...
  3. CD8+ T Cell Immunity to Cytomegalovirus
    Stanley Riddell; Fiscal Year: 2009
    ..infection is a major cause of morbidity and mortality in patients who undergo allogeneic hematopoietic stem cell transplantation and require systemic corticosteroids to treat graft versus host disease...
  4. Cytokine Induced CD26 Modulation of Adult Hematopoietic Stem Cell Trafficking
    Kent Christopherson; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Hematopoietic stem cell transplantation (HSCT) is a successful treatment option for many patients with severe hematologic diseases...
  5. Molecular Mechanisms of Blood Cell Transfusion
    LESLIE ERIC SILBERSTEIN; Fiscal Year: 2010
    ..serological investigation of blood to a clinical discipline that involves cellular therapies for hematopoietic stem cell transplantation and immunotherapy for infectious diseases and cancer...
  6. WI State Public Health Lab Capacity for SCID Screening
    CHARLES DENNIS BROKOPP; Fiscal Year: 2010
    ..b>Hematopoietic stem cell transplantation (HSCT) is highly curative (up to 95% survival) only if the SCID infants are recognized early in ..
  7. WI State Public Health Lab Capacity for SCID Screening
    CHARLES BROKOPP; Fiscal Year: 2009
    ..b>Hematopoietic stem cell transplantation (HSCT) is highly curative (up to 95% survival) only if the SCID infants are recognized early in ..
  8. System for Rapid Generation of Aptamers for Transplant Therapies
    KAREN QIAN; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Autologous hematopoietic stem cell transplantation (HSCT) has been an important treatment option for many patients with hematologic malignancies and solid tumors such as acute myeloid leukemia, ..
  9. Cytokine regulation of transplanted lymphoid progenitors
    Kenneth Weinberg; Fiscal Year: 2003
    Following hematopoietic stem cell transplantation (HSCT), there are two pathways for T lymphocyte development...
  10. Training Patients and Partners for HSCT: A Novel Coping Skills Intervention
    Catalina Lawsin; Fiscal Year: 2007
    unreadable] DESCRIPTION (provided by applicant): Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment of hematological malignancies and related disorders with more than 40,000 transplants conducted each ..
  11. The immunobiology of CD4+ CD25+ T regulatory cells
    Thomas R Malek; Fiscal Year: 2011
    ..to inhibit unwanted immune responses that occur during autoimmune disease or as a consequence of hematopoietic stem cell transplantation (HSCT) or tissue transplant rejection reactions...
  12. Retroviral Vector-mediated Liver Gene Therapy for MPS I
    KATHERINE PONDER; Fiscal Year: 2009
    ..b>Hematopoietic stem cell transplantation can reduce some manifestations, but has a 15% mortality rate, costs $130,000, and requires a ..
  13. Retroviral Vector-mediated Liver Gene Therapy for MPS I
    Katherine P Ponder; Fiscal Year: 2010
    ..b>Hematopoietic stem cell transplantation can reduce some manifestations, but has a 15% mortality rate, costs $130,000, and requires a ..
  14. Imaging Infused CD19 Specific T Cells in the Tumor
    LAURENCE COOPER; Fiscal Year: 2007
    ..This will help investigators gauge the efficacy of T-cell immunotherapies. [unreadable] [unreadable] [unreadable]..
  15. HDL Dysfunction and Vascular Inflammation
    Kirkwood Pritchard; Fiscal Year: 2006
    ..b>Hematopoietic stem cell transplantation (HSCT) of SCD into genetically engineered mice will be used to test alternative hypotheses that ..
  16. HDL Dysfunction and Vascular Inflammation
    Kirkwood Pritchard; Fiscal Year: 2007
    ..b>Hematopoietic stem cell transplantation (HSCT) of SCD into genetically engineered mice will be used to test alternative hypotheses that ..
  17. HDL Dysfunction and Vascular Inflammation
    Kirkwood Pritchard; Fiscal Year: 2009
    ..b>Hematopoietic stem cell transplantation (HSCT) of SCD into genetically engineered mice will be used to test alternative hypotheses that ..
  18. Phase I Clinical Trial: Safety of Subconjunctival Cyclosporine Implant for GVHD
    Darby Thompson; Fiscal Year: 2010
    ..Host Disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (SCT) commonly affecting the skin, liver, gastrointestinal tract, and eye...
  19. T-cell Therapy for B-lineage Acute Lymphoblastic Leukemia
    Laurence J N Cooper; Fiscal Year: 2010
    ..LAY SUMMARY: We will infuse CD19-specific T cells after transplantation to improve survival for patients with acute lymphoblastic leukemia. ..
  20. Hematopoietic Stem Cell Transplantation in Osteogenesis Imperfecta
    Meenal Mehrotra; Fiscal Year: 2010
    ..Long term, these findings have the potential to identify HSC transplantation, and not the transplantation of MSCs or progenitor cells, as the therapy of choice for this collagen disorder. ..
  21. Role of PGE2 and other eicosanoids in hematopoietic stem cell function
    Louis M Pelus; Fiscal Year: 2010
    ..We believe that the information we derive can be directly translated to improve hematopoietic stem cell transplantation.Eicosanoids are physiological lipids that include prostaglandins, prostacyclins, thromboxanes, ..
  22. Correction of neural abnormalities in Hurler syndrome
    Pankaj Gupta; Fiscal Year: 2002
    ..These neuro-psychological abnormalities are not adequately corrected by hematopoietic stem cell transplantation (via bone marrow transplantation; BMT)...
  23. Novel Hematopoietic Conditioning Agents for Treatment of Hematological Diseases
    Olga B Chernova; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Hematopoietic stem cell transplantation (HSCT) has increased the survival of children and adults afflicted with malignant and non-malignant hematological diseases...
  24. Correction of neural abnormalities in Hurler syndrome
    Pankaj Gupta; Fiscal Year: 2003
    ..These neuro-psychological abnormalities are not adequately corrected by hematopoietic stem cell transplantation (via bone marrow transplantation; BMT)...
  25. Population Pharmacokinetics/Pharmacodynamics in Nonablative Stem Cell Recipients
    Jeannine McCune; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Nonablative hematopoietic stem cell transplantation (HCT) with an unrelated donor graft has greatly expanded the number of patients suffering from hematologic diseases and malignancies who can be ..
  26. Population Pharmacokinetics/Pharmacodynamics in Nonablative Stem Cell Recipients
    Jeannine McCune; Fiscal Year: 2009
    PROJECT SUMMARY Nonablative hematopoietic stem cell transplantation (HCT) with an unrelated donor graft has greatly expanded the number of patients suffering from hematologic diseases and malignancies who can be cured by HCT...
  27. Population Pharmacokinetics/Pharmacodynamics in Nonablative Stem Cell Recipients
    Jeannine S McCune; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Nonablative hematopoietic stem cell transplantation (HCT) with an unrelated donor graft has greatly expanded the number of patients suffering from hematologic diseases and malignancies who can be ..
  28. Stem Cell Transplantation: Basic/Clinical Research
    Rainer Storb; Fiscal Year: 2001
    ..program of basic and clinical research to improve the short- and long-term efficacy of allogeneic hematopoietic stem cell transplantation (HSCT). Human candidate diseases for HSCT include patients with acquired (e...
  29. Stem Cell Transplantation: Basic/Clinical Research
    Rainer Storb; Fiscal Year: 2002
    ..program of basic and clinical research to improve the short- and long-term efficacy of allogeneic hematopoietic stem cell transplantation (HSCT). Human candidate diseases for HSCT include patients with acquired (e...
  30. Stem Cell Transplantation: Basic/Clinical Research
    Rainer Storb; Fiscal Year: 2005
    ..program of basic and clinical research to improve the short- and long-term efficacy of allogeneic hematopoietic stem cell transplantation (HSCT). Human candidate diseases for HSCT include patients with acquired (e...
  31. Stem Cell Transplantation: Basic/Clinical Research
    Rainer Storb; Fiscal Year: 2003
    ..program of basic and clinical research to improve the short- and long-term efficacy of allogeneic hematopoietic stem cell transplantation (HSCT). Human candidate diseases for HSCT include patients with acquired (e...
  32. Stem Cell Transplantation: Basic/Clinical Research
    Rainer Storb; Fiscal Year: 2004
    ..program of basic and clinical research to improve the short- and long-term efficacy of allogeneic hematopoietic stem cell transplantation (HSCT). Human candidate diseases for HSCT include patients with acquired (e...
  33. Positive and Negative Regulation of Natural Killer Cells After BMT
    WILLIAM JOSEPH MURPHY; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Hematopoietic stem cell transplantation (HSCT) is increasingly used in cancer therapy and has been shown to provide significant graft-versus-tumor effects for several cancers...
  34. GM-CSF secreting tumor cell vaccines to enhance post-transplant anti-CLL immunity
    Catherine Wu; Fiscal Year: 2009
    ..destruction as demonstrated by observations of the graft-versus-leukemia (GvL) effect after hematopoietic stem cell transplantation and donor lymphocyte infusion (DLI)...
  35. INFLAMMATORY MONOCYTES IN ALLO-HSCT
    Eric G Pamer; Fiscal Year: 2011
    ..Reconstitution of circulating monocyte subsets varies between patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT) and we postulate that this has implications for susceptibility to infection...
  36. Beta-Globin Gene Correction Using Peptide Nucleic Acids for the Treatment of Sick
    GERALD FRANCIS VOVIS; Fiscal Year: 2010
    ..Allogeneic hematopoietic stem cell transplantation is curative, although such a treatment typically requires an HLA-matched donor, is associated ..
  37. Immune Recovery Following LLME Treated Cell Therapy
    Joanne Filicko; Fiscal Year: 2003
    Allogeneic hematopoietic stem cell transplantation (HSCT) is the preferred therapy for a variety of disorders...
  38. Immune Recovery Following LLME Treated Cell Therapy
    Joanne Filicko; Fiscal Year: 2005
    Allogeneic hematopoietic stem cell transplantation (HSCT) is the preferred therapy for a variety of disorders...
  39. Immune Recovery Following LLME Treated Cell Therapy
    Joanne Filicko; Fiscal Year: 2002
    Allogeneic hematopoietic stem cell transplantation (HSCT) is the preferred therapy for a variety of disorders...
  40. Immune Recovery Following LLME Treated Cell Therapy
    Joanne Filicko; Fiscal Year: 2004
    Allogeneic hematopoietic stem cell transplantation (HSCT) is the preferred therapy for a variety of disorders...
  41. Characterization of A Novel 65kDa E-selectin Ligand on G-CSF Mobilized Leukocytes
    Robert Sackstein; Fiscal Year: 2007
    ..blood (MPB) has replaced traditional bone marrow harvest as the preferred source of cells for hematopoietic stem cell transplantation. Though generally considered to be a safer alternative to harvest, there are increasing ..
  42. Effect of recipient age /graft vs host disease post BMT
    RAYMOND HUTCHISON; Fiscal Year: 2001
    Murine models of hematopoietic stem cell transplantation will be utilized to investigate the association between advancing age and more severe graft-vs.-host disease (GVHD)...
  43. ADHESION MOLECULES MEDIATING SKIN TROPISM IN ACUTE GVHD
    Robert Sackstein; Fiscal Year: 2002
    DESCRIPTION: (Applicant's Abstract) Allogeneic hematopoietic stem cell transplantation (HSCT) is curative therapy for hematologic malignancies, aplastic anemia and a variety of genetic conditions; however, significant treatment-related ..
  44. ADHESION MOLECULES MEDIATING SKIN TROPISM IN ACUTE GVHD
    Robert Sackstein; Fiscal Year: 2001
    DESCRIPTION: (Applicant's Abstract) Allogeneic hematopoietic stem cell transplantation (HSCT) is curative therapy for hematologic malignancies, aplastic anemia and a variety of genetic conditions; however, significant treatment-related ..
  45. ADHESION MOLECULES MEDIATING SKIN TROPISM IN ACUTE GVHD
    Robert Sackstein; Fiscal Year: 2003
    DESCRIPTION: (Applicant's Abstract) Allogeneic hematopoietic stem cell transplantation (HSCT) is curative therapy for hematologic malignancies, aplastic anemia and a variety of genetic conditions; however, significant treatment-related ..
  46. IN UTERO STEM CELL TRANSPLANTATION
    Esmail D Zanjani; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): In utero hematopoietic stem cell transplantation (IUSCT) is a promising therapeutic approach for many genetic disorders...
  47. TRANSPLANTS FOR MYELODYSPLASIA AND MYELOFIBROSIS
    H Deeg; Fiscal Year: 2001
    b>Hematopoietic stem cell transplantation (HSCT) is currently the only therapeutic modality with curative potential in patients with myelodysplastic syndromes (MDS)...
  48. IN UTERO STEM CELL TRANSPLANTATION
    Esmail Zanjani; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): In utero hematopoietic stem cell transplantation (IUSCT) is a promising therapeutic approach for many genetic disorders...
  49. TRANSPLANTS FOR MYELODYSPLASIA AND MYELOFIBROSIS
    H Deeg; Fiscal Year: 2003
    b>Hematopoietic stem cell transplantation (HSCT) is currently the only therapeutic modality with curative potential in patients with myelodysplastic syndromes (MDS)...
  50. Krabbe disease: Combined therapies for the central and peripheral nervous systems
    David Wenger; Fiscal Year: 2009
    ..The only treatment currently available for some patients is hematopoietic stem cell transplantation (HSCT)...
  51. Krabbe disease: Combined therapies for the central and peripheral nervous systems
    David A Wenger; Fiscal Year: 2010
    ..The only treatment currently available for some patients is hematopoietic stem cell transplantation (HSCT)...
  52. Nonmyeloablative Transplants for Nomalignant Disorders
    Rainer Storb; Fiscal Year: 2004
    b>Hematopoietic stem cell transplantation (HSCT) is currently the only therapeutic modality with curative potential in patients with myelodysplastic syndromes (MDS)...
  53. Cincinnati Center for Excellence in Molecular Hematology
    Yi Zheng; Fiscal Year: 2010
    ..cell biology, basic research in signaling and clinical care in hematology, allergy/immunology and hematopoietic stem cell transplantation. This focus has been greatly strengthened by recruitment of over 50 faculty in these areas in the ..
  54. Phase I Clinical Trial: Safety of Subconjunctival Cyclosporine Implant for GVHD
    Darby Thompson; Fiscal Year: 2009
    Graft-vs.-Host Disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (SCT) commonly affecting the skin, liver, gastrointestinal tract, and eye...
  55. HGF Induces Robust Human Thymopoiesis in Mice
    Jan Nolta; Fiscal Year: 2003
    Over the past decade, the use of immune deficient mice as recipients for human hematopoietic stem cell transplantation has dramatically improved stem cell research...
  56. HGF Induces Robust Human Thymopoiesis in Mice
    Jan Nolta; Fiscal Year: 2004
    Over the past decade, the use of immune deficient mice as recipients for human hematopoietic stem cell transplantation has dramatically improved stem cell research...
  57. CELLULAR CORRECTION OF CONGENITAL HEMATOPOIETIC DISORDERS
    Eva Guinan; Fiscal Year: 2001
    When a histocompatible donor is available, allogeneic hematopoietic stem cell transplantation (HSCT) provides a highly successful modality with which to correct congenital disorders of hematopoiesis...
  58. CELLULAR CORRECTION OF CONGENITAL HEMATOPOIETIC DISORDERS
    Eva Guinan; Fiscal Year: 2000
    When a histocompatible donor is available, allogeneic hematopoietic stem cell transplantation (HSCT) provides a highly successful modality with which to correct congenital disorders of hematopoiesis...
  59. CELLULAR CORRECTION OF CONGENITAL HEMATOPOIETIC DISORDERS
    Eva Guinan; Fiscal Year: 2002
    When a histocompatible donor is available, allogeneic hematopoietic stem cell transplantation (HSCT) provides a highly successful modality with which to correct congenital disorders of hematopoiesis...
  60. IL-12-Faciliated Hematopoietic Recovery Following Myeloablative Therapy
    Dan Douer; Fiscal Year: 2007
    ..provided by applicant): Intensive myeloablative cytotoxic treatment followed by autologous hematopoietic stem cell transplantation (HSCT) is frequently used in clinical practice to cure or improve survival of hematological ..
  61. Optimizing Nonmyeloablative Stem Cell Transplantation
    Marco Mielcarek; Fiscal Year: 2003
    ..have been impressed by the toxicities associated with conditioning regimens used for conventional hematopoietic stem cell transplantation (HSCT)...
  62. Optimizing Nonmyeloablative Stem Cell Transplantation
    Marco Mielcarek; Fiscal Year: 2007
    ..have been impressed by the toxicities associated with conditioning regimens used for conventional hematopoietic stem cell transplantation (HSCT)...
  63. NK Receptors and Bone Marrow Transplant Outcome
    Katharine Hsu; Fiscal Year: 2005
    ..research interest is in the impact of killer immunoglobulin-like receptors (KIR) on allogeneic hematopoietic stem cell transplantation. AIIogeneic hematopoietic stem cell transplantation (AHSCT) is a valuable therapy for acute ..
  64. NK Receptors and Bone Marrow Transplant Outcome
    Katharine Hsu; Fiscal Year: 2006
    ..research interest is in the impact of killer immunoglobulin-like receptors (KIR) on allogeneic hematopoietic stem cell transplantation. AIIogeneic hematopoietic stem cell transplantation (AHSCT) is a valuable therapy for acute ..
  65. NK Receptors and Bone Marrow Transplant Outcome
    Katharine Hsu; Fiscal Year: 2007
    ..research interest is in the impact of killer immunoglobulin-like receptors (KIR) on allogeneic hematopoietic stem cell transplantation. AIIogeneic hematopoietic stem cell transplantation (AHSCT) is a valuable therapy for acute ..
  66. NK Receptors and Bone Marrow Transplant Outcome
    Katharine Hsu; Fiscal Year: 2004
    ..research interest is in the impact of killer immunoglobulin-like receptors (KIR) on allogeneic hematopoietic stem cell transplantation. AIIogeneic hematopoietic stem cell transplantation (AHSCT) is a valuable therapy for acute ..
  67. Optimizing Nonmyeloablative Stem Cell Transportation
    Marco Mielcarek; Fiscal Year: 2005
    ..have been impressed by the toxicities associated with conditioning regimens used for conventional hematopoietic stem cell transplantation (HSCT)...
  68. Optimizing Nonmyeloablative Stem Cell Transportation
    Marco Mielcarek; Fiscal Year: 2004
    ..have been impressed by the toxicities associated with conditioning regimens used for conventional hematopoietic stem cell transplantation (HSCT)...
  69. Optimizing Nonmyeloablative Stem Cell Transportation
    Marco Mielcarek; Fiscal Year: 2006
    ..have been impressed by the toxicities associated with conditioning regimens used for conventional hematopoietic stem cell transplantation (HSCT)...
  70. Vaccine-enhanced DLI to prevent cancer recurrence after stem cell transplantation
    John Roback; Fiscal Year: 2006
    ..provided by applicant): Delayed reconstitution of antigen-specific immunity following allogeneic hematopoietic stem cell transplantation (HSCT) predisposes patients to opportunistic infections and tumor recurrence...
  71. ADHESION MOLECULES MEDIATING SKIN TROPISM IN ACUTE GVHD
    Robert Sackstein; Fiscal Year: 2000
    DESCRIPTION: (Applicant's Abstract) Allogeneic hematopoietic stem cell transplantation (HSCT) is curative therapy for hematologic malignancies, aplastic anemia and a variety of genetic conditions; however, significant treatment-related ..
  72. Assessment of Immunity to Vaccinia and MVA
    Raphael Dolin; Fiscal Year: 2003
    ..with atopic dermatitis or patients with hematologic malignancies and immune deficiency after hematopoietic stem cell transplantation. The studies will measure neutralizing and other binding antibodies, lymphoproliferative ..
  73. Retroviral Vector-mediated Liver Gene Therapy for MPS I
    KATHERINE PONDER; Fiscal Year: 2007
    ..b>Hematopoietic stem cell transplantation can reduce certain manifestations, but has a 20% mortality rate...
  74. Graft versus Host Disease Biomarkers: Prediction of Onset and Response to Therapy
    Sophie Paczesny; Fiscal Year: 2010
    ..Allogeneic hematopoietic stem cell transplantation is a potentially curative therapy for many malignant diseases but its clinical utility has been ..
  75. IMMUNOGENETICS OF MARROW ALLOGRAFTING
    John Hansen; Fiscal Year: 2003
    b>Hematopoietic stem cell transplantation (HSCT) has become life saving therapy for patients with various congenital, acquired and malignant diseases of the immune and hematopoietic systems...
  76. IMMUNOGENETICS OF MARROW ALLOGRAFTING
    John Hansen; Fiscal Year: 2004
    b>Hematopoietic stem cell transplantation (HSCT) has become life saving therapy for patients with various congenital, acquired and malignant diseases of the immune and hematopoietic systems...
  77. Strategy to Cure Type 1 Diabetes
    Zhiguang Guo; Fiscal Year: 2003
    Recent developments in hematopoietic stem cell transplantation provide a new therapeutic opportunity for treating type 1 diabetes...
  78. Strategy to Cure Type 1 Diabetes
    Zhiguang Guo; Fiscal Year: 2002
    Recent developments in hematopoietic stem cell transplantation provide a new therapeutic opportunity for treating type 1 diabetes...
  79. Graft versus Host Disease Biomarkers: Prediction of Onset and Response to Therapy
    Sophie Paczesny; Fiscal Year: 2009
    ..Allogeneic hematopoietic stem cell transplantation is a potentially curative therapy for many malignant diseases but its clinical utility has been ..
  80. IMMUNOGENETICS OF MARROW ALLOGRAFTING
    John Hansen; Fiscal Year: 2005
    b>Hematopoietic stem cell transplantation (HSCT) has become life saving therapy for patients with various congenital, acquired and malignant diseases of the immune and hematopoietic systems...
  81. IMMUNOGENETICS OF MARROW ALLOGRAFTING
    John Hansen; Fiscal Year: 2002
    b>Hematopoietic stem cell transplantation (HSCT) has become life saving therapy for patients with various congenital, acquired and malignant diseases of the immune and hematopoietic systems...
  82. Ex Vivo Alloanergization to Improve Immunity After Haploidentical Transplant
    Eva C Guinan; Fiscal Year: 2010
    Allogeneic hematopoietic stem cell transplantation (HSCT) is curative for many patients with malignant diseases. However, many patients lack HLA-matched donors, particularly those of minority or mixed race or ethnicity...
  83. Ex Vivo Alloanergization to Improve Immunity After Haploidentical Transplant
    Eva Guinan; Fiscal Year: 2009
    Allogeneic hematopoietic stem cell transplantation (HSCT) is curative for many patients with malignant diseases. However, many patients lack HLA-matched donors, particularly those of minority or mixed race or ethnicity...
  84. IMMUNOGENETICS OF MARROW ALLOGRAFTING
    John Hansen; Fiscal Year: 2006
    b>Hematopoietic stem cell transplantation (HSCT) has become life saving therapy for patients with various congenital, acquired and malignant diseases of the immune and hematopoietic systems...
  85. Allogeneic Stem Cell Transplants for HPV+Cervical Cancer
    Alexander Fefer; Fiscal Year: 2002
    ..allogeneic adoptive T-cell immunotherapy in the context of non-myeloablative allogeneic hematopoietic stem cell transplantation (NST) for the treatment of non-hematologic malignancies...
  86. Optimizing Immunotherapy for Neuroblastoma after BMT
    Bryon Johnson; Fiscal Year: 2009
    ..For advanced disease, autologous hematopoietic stem cell transplantation (HSCT) has resulted in significantly better event-free survival as compared to maintenance ..
  87. Maternal and fetal immune responses to in utero HSC transplantation
    Tippi Mackenzie; Fiscal Year: 2010
    ..In the mouse model of in utero hematopoietic stem cell transplantation (IUHSCTx), we and others have shown that the immune response of the host limits engraftment...
  88. Molecular targeting agents in GVHD/GVT: Role of cytokines and T cell subsets
    WILLIAM JOSEPH MURPHY; Fiscal Year: 2012
    Allogeneic hematopoietic stem cell transplantation (HSCT) is currently used for the treatment of a variety hematologic malignancies...
  89. Molecular targeting agents in GVHD/GVT: Role of cytokines and T cell subsets
    WILLIAM JOSEPH MURPHY; Fiscal Year: 2010
    Allogeneic hematopoietic stem cell transplantation (HSCT) is currently used for the treatment of a variety hematologic malignancies...
  90. Molecular targeting agents in GVHD/GVT: Role of cytokines and T cell subsets
    William Murphy; Fiscal Year: 2009
    Allogeneic hematopoietic stem cell transplantation (HSCT) is currently used for the treatment of a variety hematologic malignancies...
  91. graft-verus-host disease and graft-versus-leukemia
    THEA FRIEDMAN; Fiscal Year: 2004
    Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for a variety of hematological malignancies...
  92. Identification of stromal responses during castration-induced thymic regrowth.
    Howard Petrie; Fiscal Year: 2009
    ..Decreased capacity to make new T cells is also a substantial limitation in hematopoietic stem cell transplantation, which is an established therapy for diseases like leukemia, and an emerging therapy for ..
  93. graft-verus-host disease and graft-versus-leukemia
    THEA FRIEDMAN; Fiscal Year: 2004
    Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for a variety of hematological malignancies...
  94. Clinical Epidemiology and Pathogenesis of Asymptomatic HSV
    Lawrence Corey; Fiscal Year: 2009
    ..immunocompetent patients, pregnant women, HIV positive patients on/off HAART, and patients post hematopoietic stem cell transplantation (HSCT)...
  95. graft-verus-host disease and graft-versus-leukemia
    THEA FRIEDMAN; Fiscal Year: 2003
    Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for a variety of hematological malignancies...
  96. graft-verus-host disease and graft-versus-leukemia
    THEA FRIEDMAN; Fiscal Year: 2006
    Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for a variety of hematological malignancies...
  97. Identification of stromal responses during castration-induced thymic regrowth.
    Howard T Petrie; Fiscal Year: 2010
    ..Decreased capacity to make new T cells is also a substantial limitation in hematopoietic stem cell transplantation, which is an established therapy for diseases like leukemia, and an emerging therapy for ..
  98. Clinical Epidemiology and Pathogenesis of Asymptomatic HSV
    Lawrence Corey; Fiscal Year: 2010
    ..immunocompetent patients, pregnant women, HIV positive patients on/off HAART, and patients post hematopoietic stem cell transplantation (HSCT)...
  99. graft-verus-host disease and graft-versus-leukemia
    THEA FRIEDMAN; Fiscal Year: 2005
    Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for a variety of hematological malignancies...